ImmunoMolecular Therapeutics, Inc.
Woburn, MA · Founded 2015 · CIK 0001646606 · Biotech · Private
Small molecule oral immunotherapy (L-MDOPA enantiomer) that blocks HLA-DQ2 to prevent immune-mediated destruction of insulin-producing beta cells in type 1 diabetes
imtherapeutics.com →- Grants
- $450K
- 2 awards
- Sector median: 1
- Raised
- $11M
- 4 Form D · Nov 2020
- 71 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 11
- 3 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $350,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · HLA Allele Specific Immune Modulation for Type 1 Diabetes | $224,991 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · HLA Allele Specific Immune Modulation for Type 1 Diabetes | $224,991 | |
| Private capital raised | Form D · SEC | $2,999,992 | |
| Private capital raised | Form D · SEC | $7,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2138 | SGN, Inc. | — | $3.8M |
| 2139 | NOVATARG, INC. | — | — |
| 2140 | Helix Alternative Technologies Inc. | — | $6.0M |
| 2141 | ImmunoMolecular Therapeutics, Inc. | — | $11M |
| 2142 | CELLECHO INC | — | — |
| 2143 | Calico | — | — |
| 2144 | Scinai Immunotherapeutics Ltd. | — | $3.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jonathan BehrDirector
- Jason DingesDirector
- Sean DohertyDirector
- Peter GottliebDirector · Executive Officer · Promoter
- Aaron MichelsExecutive Officer · Promoter
- Steve OrndorffDirector · Executive Officer · Promoter
- Ed OrrDirector · Promoter
- Nandan PadukoneDirector · Executive Officer
- Tom SheaExecutive Officer
Patents
- Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2granted
- Compounds And Methods For Treating Autoimmune Disorders By Targeting HLA-DQ2granted
- Methods for Producing D-alpha-Methyldopagranted
- Compounds And Methods For Treating Autoimmune Disorders By Targeting HLA-DQ2application
- Compounds And Methods For Treating Autoimmune Disorders By Targeting HLA-DQ2application
- Methods For Producing D-alpha-methyldopaapplication
- Compounds And Methods For Treating Autoimmune Disorders By Targeting HLA-DQ2application
- Compounds And Methods For Treating Autoimmune Disorders By Targeting HLA-DQ2application
- Compounds And Methods For Treating Autoimmune Disorders By Targeting HLA-DQ2application
- Methods For Producing D-alpha-methyldopaapplication
- Compounds And Methods For Treating Autoimmune Disorders By Targeting HLA-DQ2application
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.